Compare CVS Health Corp (CVS) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Newmont Corporation — how do they compare? CVS Health Corp trades at $93.65 (market cap $122.36B), while Newmont Corporation trades at $117.92 (market cap $123.56B). The key difference: CVS Health Corp and Newmont Corporation are close in size by market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| CVS | NEM | |
|---|---|---|
Market Cap | $122.36B | $123.56B |
Sector | Health | Basic Materials |
52-Week High | $110.60 | $131.95 |
52-Week Low | $65.51 | $67.38 |
Enterprise Value | $184.71B | $120.14B |
Dividend Yield | 2.78% | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Newmont Corporation (NEM) trades at $112.98, up 7.16% over 24 hours, reflecting strong momentum amid record gold prices. The stock exhibits bullish technical signals with moving averages aligned positively, though oscillators suggest overbought conditions. Fundamentally, the company reported robust earnings, with Q2 2026 EPS of $2.10 beating estimates, and annual revenue growth from $11.9B in 2022 to $22.7B in 2025. Recent news highlights a $1.95B settlement with Barrick Mining, resolving Nevada disputes and enhancing strategic flexibility.
Outlook remains positive with a consensus price target of $133, implying 17.8% upside, supported by 75.7% analyst buy ratings. Key opportunities include strong free cash flow generation and production guidance maintenance. Risks involve potential cost pressures in H2 2026, gold price volatility, and insider stock sales by the CEO and CFO in early August 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
